HSP 90-Alpha and Serotransferrin as Potential Biomarkers for Predicting IL-17 Inhibitor Response in Non-Radiographic Axial Spondyloarthritis: A Retrospective Analysis.

Background: Non-radiographic axial spondyloarthritis (nr-axSpA) is an early stage of axial spondyloarthritis characterized by the absence of definitive radiographic changes. Interleukin-17 inhibitors (IL-17i) have shown efficacy in treating nr-axSpA, but a significant proportion of patients fail to respond. Identifying predictive biomarkers for IL-17i response is crucial for optimizing treatment strategies.

CXCR4-Expressing Mesenchymal Stem Cells Derived Nanovesicles for Rheumatoid Arthritis Treatment.

Cell membrane camouflage technology, which a demonstrated value for the bionic replication of natural cell membrane properties, is an active area of ongoing research readily applicable to nanomedicine. How to realize immune evasion, slow down the clearance from the body, and improve targeting are still worth great efforts for this technology. Herein, novel cell membrane-mimicked nanovesicles from genetically engineered mesenchymal stem cells (MSCs) are presented as a potential anti-inflammatory platform for rheumatoid arthritis (RA) management.

Biomimetic liposomes hybrid with erythrocyte membrane modulate dendritic cells to ameliorate systemic lupus erythematosus.

Dendritic cells (DCs)-based immunotherapy has shown immense promise in systemic lupus erythematosus (SLE) treatment. However, existing carrier strategies such as polymers, liposomes, and polypeptides, are difficult to achieve active targeting to DCs due to their intricate interaction with biological systems. Since DCs represent a class of phagocytes responsible for the removal of senescent or damaged erythrocytes, we hypothesize that hybrid vesicles containing erythrocytes membrane components could be presented to be potent drug carriers to target DCs specifically.